Hadassah Women's Zionist Organization of America

xCAT IQ Installed at Hadassah University Hospital

Retrieved on: 
Thursday, September 1, 2022
Hebrew University of Jerusalem, University, IQ, Fracture, 3D, Bed, DDS, Oral, ANN, Rothschild, Eleazar Sukenik, World Zionist Organization, Oral and maxillofacial surgery, Bone fracture, CT, Hebrew language, Department, Human, Hospital, Multimedia, Cone beam computed tomography, MD, Cholesteatoma, Surgeon, High-dependency unit, Paola Lattus, School, Hadassah Medical Center, XCAT, Prophet, Street of the Prophets, MS, Otorhinolaryngology, Dentistry, Patient, Medical imaging, Health, DMD, Hadassah Women's Zionist Organization of America

Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.

Key Points: 
  • Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.
  • With high resolution down to 70 microns and an extremely small footprint, the xCAT IQ is uniquely suited to meet the needs of the Hadassah clinicians.
  • The implementation of xCAT IQ was largely facilitated by the efforts of Prof. Yoram Weiss, MD, Director General of the Hadassah Medical Organization.
  • Since the establishment of Hadassah's first hospital on Jerusalem's Neviim Street (Street of the Prophets) - a gift of the Rothschild family in 1918 - the Hadassah University Medical Center has expanded to include two University hospitals in Jerusalem - located on Mt.

P-Cure to support Hadassah Medical Organization in being the first to provide Proton Therapy to cancer patients in Israel

Retrieved on: 
Tuesday, June 28, 2022
Proton, TEL, FDA, Hadassah Medical Center, Patient, Eleazar Sukenik, Asian Pacific Development Center, Head, Travel, Brain, Hebrew University of Jerusalem, Cancer, Ministry, Neck, Proton therapy, CE, Neoplasm, Radiation, Physician, Ethics committee, Medical imaging, Health, Hadassah Women's Zionist Organization of America

TEL AVIV, Israel, June 28, 2022 /PRNewswire-PRWeb/ -- P-Cure Ltd. ("P-Cure"), the provider of the most compact 360° gantry-less adaptive proton therapy system that can be installed in a linac vault, announced today a collaboration with Hadassah Medical Organization ("Hadassah") in Jerusalem. The collaboration will provide cancer patients in Israel with access to proton therapy, the most targeted type of radiation therapy. The treatments will be carried out as a clinical research initiative with no economic burden to patients or medical insurers.

Key Points: 
  • The collaboration will provide cancer patients in Israel with access to proton therapy, the most targeted type of radiation therapy.
  • The treatments will be performed by the medical team of Hadassah at the P-Cure Clinical Research and Development Center.
  • Until now the patients in Israel, who were found eligible for proton therapy, have to travel abroad.
  • Proton therapy has proven its clinical benefits since the first hospital-based proton center started treating patients 32 years ago.

Israeli companies present breakthrough medical technologies - IMPROVATE Life-Saving Technologies Conference: Cell therapies, bio-engineering, big-data analytics creating future of medicine

Retrieved on: 
Thursday, July 29, 2021
Zionism, Hadassah Medical Center, Hadassah Women's Zionist Organization of America, Hebrew University of Jerusalem, Mount Scopus

Prof. Ze'ev Rotstein, Director of Hadassah Medical Center, addressed the conference on how better data creates better care.

Key Points: 
  • Prof. Ze'ev Rotstein, Director of Hadassah Medical Center, addressed the conference on how better data creates better care.
  • Big data is not only the clinical data of the patients, but we are deepening our understanding of all the genomics.
  • Former Bulgarian President and IMPROVATE advisory board member Rosen Plevneliev said the European market holds huge opportunities for Israeli companies.
  • IMedishas developed Duali-Q, a revolutionary medical innovation that promotes early detection of cancer and other life-threatening diseases using AI technology.

Israeli companies present breakthrough medical technologies - IMPROVATE Life-Saving Technologies Conference: Cell therapies, bio-engineering, big-data analytics creating future of medicine

Retrieved on: 
Thursday, July 29, 2021
Zionism, Hadassah Medical Center, Hadassah Women's Zionist Organization of America, Hebrew University of Jerusalem, Mount Scopus

Prof. Ze'ev Rotstein, Director of Hadassah Medical Center, addressed the conference on how better data creates better care.

Key Points: 
  • Prof. Ze'ev Rotstein, Director of Hadassah Medical Center, addressed the conference on how better data creates better care.
  • Big data is not only the clinical data of the patients, but we are deepening our understanding of all the genomics.
  • Former Bulgarian President and IMPROVATE advisory board member Rosen Plevneliev said the European market holds huge opportunities for Israeli companies.
  • IMedishas developed Duali-Q, a revolutionary medical innovation that promotes early detection of cancer and other life-threatening diseases using AI technology.

Major Healthcare Providers in Israel Choose Sectra's Digital Pathology Solution for Full-scale Primary Diagnostics

Retrieved on: 
Thursday, July 9, 2020
Hadassah Women's Zionist Organization of America, General Zionism, Madoff investment scandal, Assuta Medical Center, Hadassah Medical Center, Zionism, Health in Israel

It reduces variation and increases efficiency in primary diagnostics, thereby improving fields such as cancer care.

Key Points: 
  • It reduces variation and increases efficiency in primary diagnostics, thereby improving fields such as cancer care.
  • The systems at Hadassah Medical Center and Assuta Medical Center were sold by Sectra's distribution partner in Israel, Medi-Far Healthcare Solutions.
  • Hadassah Medical Center performs about 40,000 pathology examinations per year across its two university hospitals and 120 clinics located in Jerusalem.
  • The digital solution provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements.

Major Healthcare Providers in Israel Choose Sectra's Digital Pathology Solution for Full-scale Primary Diagnostics

Retrieved on: 
Thursday, July 9, 2020
Hadassah Women's Zionist Organization of America, General Zionism, Madoff investment scandal, Assuta Medical Center, Hadassah Medical Center, Zionism, Health in Israel

It reduces variation and increases efficiency in primary diagnostics, thereby improving fields such as cancer care.

Key Points: 
  • It reduces variation and increases efficiency in primary diagnostics, thereby improving fields such as cancer care.
  • The systems at Hadassah Medical Center and Assuta Medical Center were sold by Sectra's distribution partner in Israel, Medi-Far Healthcare Solutions.
  • Hadassah Medical Center performs about 40,000 pathology examinations per year across its two university hospitals and 120 clinics located in Jerusalem.
  • The digital solution provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements.

Nanox Signs Agreement With Hadassah Medical Organization for the Development of Novel Early-detection Protocols for the Nanox.ARC

Retrieved on: 
Monday, April 27, 2020
Science, Biotechnology, Research, Surgery, Health, Medical devices, Hospitals, Other Health, Hadassah Women's Zionist Organization of America, Hadassah Medical Center, Medical imaging, Zionism, Medicine, Full-body CT scan, Nanox, Hadassah Hospital

Hadassah and its world-class medical facilities and staff were Nanoxs first choice for whom to collaborate with on innovative life-saving medical imaging procedures via full-body scans.

Key Points: 
  • Hadassah and its world-class medical facilities and staff were Nanoxs first choice for whom to collaborate with on innovative life-saving medical imaging procedures via full-body scans.
  • The scans will be delivered globally to increase accessibility to medical imaging for all socio-economic levels.
  • Hadassah treats one million patients a year regardless of race, religion, or nationality, and it is that same spirit of compassion and medical democratization that we see in Nanox, says Erez Meltzer, Chairman of the Hadassah Medical Organization.
  • Hadassah practices translational medicine, combining state-of-the-art medical and surgical care with top-level interdisciplinary research and development activity.

BioTheryX Appoints Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board

Retrieved on: 
Friday, March 6, 2020
Hadassah Women's Zionist Organization of America, Prophets in Judaism, General Zionism, Madoff investment scandal, Hadassah Medical Center, Neriah, Frank Lautenberg, Zionism, Businesspeople, Judaism, Institute For Medical Research, Israel-Canada

Dr. BenNeriah is Professor of Immunology and Cancer Research at the Lautenberg Center of Immunology of the Hebrew University, Hadassah Medical School in Jerusalem, Israel.

Key Points: 
  • Dr. BenNeriah is Professor of Immunology and Cancer Research at the Lautenberg Center of Immunology of the Hebrew University, Hadassah Medical School in Jerusalem, Israel.
  • Dr. Ben-Neriah said, "I am honored and proud to be joining the SAB of BioTheyrX.
  • Having the privilege of interacting with the entire team for the past 5 years, I must say it is truly a visionary company.
  • It has potential applicability to a broad range of diseases, including targets that have to date been considered 'undruggable'.

Israel National Research Institute, Henrietta Szold, Selects Pcysys to Automate Cyber Security Validation

Retrieved on: 
Tuesday, February 18, 2020
Hadassah Women's Zionist Organization of America, Szold, Cybercrime, Computer security, Cyberwarfare, Cyberspace

TEL AVIV, Israel, Feb. 18, 2020 /PRNewswire/ --Pcysys announces that the National Research Institute for the Behavioral Sciences, Henrietta Szold, has chosen Pcysys' Automated Penetration Testing platform, PenTera, to automate its cyber security validation efforts.

Key Points: 
  • TEL AVIV, Israel, Feb. 18, 2020 /PRNewswire/ --Pcysys announces that the National Research Institute for the Behavioral Sciences, Henrietta Szold, has chosen Pcysys' Automated Penetration Testing platform, PenTera, to automate its cyber security validation efforts.
  • The Henrietta Szold Institute partners with many governmental and academic organizations to better the education and social systems in Israel.
  • "The fact that PenTera continuously exploits each vulnerability enables an ongoing accurate cyber security health check of the network- a practice the industry has been longing for."
  • "We, at Pcysys, take pride in partnering with Israeli institutes such as Henrietta Szold to assist in their efforts to improve their cyber posture," says Sivan Harel, Regional Sales Director for Northern Europe and Israel at Pcysys.

New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 

Retrieved on: 
Friday, January 3, 2020
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical trials, Organ systems, Diabetes, Medicine, Medical specialties, Hepatitis, Non-alcoholic fatty liver disease, Endocrine diseases, Hadassah Women's Zionist Organization of America, Blood sugar level, Cuban American National Foundation

(NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadis lab demonstrate that Namodenoson induces weight loss in experimental models and normalizes glucose levels.

Key Points: 
  • (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadis lab demonstrate that Namodenoson induces weight loss in experimental models and normalizes glucose levels.
  • Dr. Safadi commented, This new weight loss data, together with the good safety profile of Namodenoson, supports its potential utilization as an anti-obesity drug.
  • New pre-clinical studies of Namodenoson showed a significant decrease in weight in both high fat diet mouse models and in diabetic rat models.
  • The Company expects to release data from the Phase II NAFLD/NASH study of Namodenoson during the first quarter of 2020.